Download presentation
Presentation is loading. Please wait.
Published byGordon Barber Modified over 9 years ago
1
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 31 Antidiabetic Drugs
2
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2
3
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus (cont’d) Symptoms Polyuria Polydipsia Polyphagia Glycosuria Unexplained weight loss Fatigue Hyperglycemia
4
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Criteria for Diagnosis of DM Symptoms of diabetes + casual plasma glucose level less than or equal to 200 mg/dL OR Fasting plasma glucose higher than or equal to 126 mg/dL OR 2-hour postload glucose level higher than or equal to 200 mg/dL during an oral glucose tolerance test
5
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Type 1 Diabetes Mellitus Lack of insulin production or Production of defective insulin Affected patients need exogenous insulin Complications Diabetic ketoacidosis (DKA) Hyperosmolar nonketotic syndrome Oral antidiabetic drugs not effective
6
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
7
Type 2 Diabetes Mellitus Most common type Caused by insulin deficiency and insulin resistance Many tissues are resistant to insulin Reduced number insulin receptors Insulin receptors less responsive
8
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Type 2 Diabetes Mellitus (cont’d) Several comorbid conditions Obesity Coronary artery disease Dyslipidemia Hypertension Microalbuminemia (protein in the urine) Enhanced conditions for embolic events (blood clots)
9
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Type 2 Diabetes Mellitus (cont’d) These comorbidities are collectively referred to as metabolic syndrome or insulin- resistance syndrome or syndrome X These comorbidities are collectively referred to as metabolic syndrome or insulin- resistance syndrome or syndrome X
10
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Major Long-Term Complications of DM (Both Types) Macrovascular (atherosclerotic plaque) Coronary arteries Coronary arteries Cerebral arteries Cerebral arteries Peripheral vessels Peripheral vessels Microvascular (capillary damage) Retinopathy Retinopathy Neuropathy Neuropathy Nephropathy Nephropathy
11
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Gestational Diabetes Hyperglycemia that develops during pregnancy Insulin must be given to prevent birth defects Usually subsides after delivery 30% of patients may develop Type 2 DM within 10 to 15 years
12
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Screening for DM Fasting plasma glucose (FPG) levels higher than or equal to 110 mg/dL but less than 126 mg/dL may indicate “prediabetes” Impaired glucose tolerance test (oral glucose challenge)
13
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Treatment for DM Type 1 Insulin therapy Type 2 Lifestyle changes Oral drug therapy Insulin when the above no longer provide glycemic control
14
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Types of Antidiabetic Drugs Insulins Oral hypoglycemic drugs Both aim to produce normal blood glucose states
15
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Insulins Function as a substitute for the endogenous hormone Effects are the same as normal endogenous insulin Restores the diabetic patient’s ability to: Metabolize carbohydrates, fats, and proteins Store glucose in the liver Convert glycogen to fat stores
16
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Insulins (cont’d) Some derived from porcine sources Most now human-derived, using recombinant DNA technologies Goal: tight glucose control To reduce the incidence of long-term complications
17
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Human-Based Insulins Rapid-Acting Most rapid onset of action (5 - 15 minutes) Most rapid onset of action (5 - 15 minutes) Shorter duration Shorter duration insulin aspart (NovoLog) insulin lispro (Humalog) insulin glulisine (Apidra) May be given SC or via continuous SC infusion pump (but not IV)
18
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Human-Based Insulins (cont’d) Short-Acting regular insulin (Humulin R, Novolin R) Onset 30 – 60 minutes The only insulin product that can be given by IV bolus, IV infusion, or even IM The only insulin product that can be given by IV bolus, IV infusion, or even IM
19
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Human-Based Insulins (cont’d) Intermediate-Acting isophane insulin suspension (also called NPH) (Humulin N, Novolin N) insulin zinc suspension (also called Lente) (Humulin L, Novolin L) Both have a cloudy appearance Both have a cloudy appearance Slower in onset and more prolonged duration than endogenous insulin Slower in onset and more prolonged duration than endogenous insulin
20
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Human-Based Insulins (cont’d) Long-Acting glargine (Lantus) Clear, colorless solution Clear, colorless solution Extended insulin zinc suspension (Ultralente, Humulin U) White, opaque solution White, opaque solution
21
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Human-Based Insulins (cont’d) Combination Insulin Products NPH 70% and regular insulin 30% (Humulin 70/30, Novolin 70/30) NPH 50% and regular insulin 50% (Humulin 50/50) insulin lispro protamine suspension 75% and insulin lispro 25% (Humalog Mix 75/25)
22
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Sliding-Scale Insulin Dosing Sliding-Scale Insulin Dosing SC short-acting or regular insulin doses adjusted according to blood glucose test results Typically used in hospitalized diabetic patients Or in patients on TPN or enteral tube feedings Subcutaneous insulin is ordered in an amount that increases as the blood glucose increases
23
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs Used for type 2 diabetes Treatment for type 2 diabetes includes lifestyle modifications Diet, exercise, smoking cessation, weight loss Oral antidiabetic drugs may not be effective unless the patient also makes behavioral or lifestyle changes
24
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs (cont’d) Sulfonylureas First generation: chlorpropamide (Diabinese), tolazamide (Tolinase), tolbutamide (Orinase) Second generation: glimepiride (Amaryl), glipizide (Glucotrol), glyburide (DiaBeta, Micronase)
25
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs (cont’d) Meglitinides repaglinide (Prandin), nateglinide (Starlix) Biguanides metformin (Glucophage)
26
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs (cont’d) Thiazolidinediones pioglitazone (Actos), rosiglitazone (Avandia) Also known as “glitazones” Alpha-glucosidase inhibitors acarbose (Precose), miglitol (Glyset)
27
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Mechanism of Action Sulfonylureas Stimulate insulin secretion from the beta cells of the pancreas, thus increasing insulin levels Beta cell function must be present Improve sensitivity to insulin in tissues Result: lower blood glucose levels First-generation drugs not used as frequently now
28
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Mechanism of Action (cont’d) Meglitinides Action similar to sulfonylureas Increase insulin secretion from the pancrease
29
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Mechanism of Action (cont’d) Biguanides Decrease production of glucose Increase uptake of glucose by tissues Do not increase insulin secretion from the pancreas (does not cause hypoglycemia)
30
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Mechanism of Action (cont’d) Thiazolidinediones Decrease insulin resistance “Insulin sensitizing drugs” Increase glucose uptake and use in skeletal muscle Inhibit glucose and triglyceride production in the liver
31
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Mechanism of Action (cont’d) Alpha-glucosidase inhibitors Reversibly inhibit the enzyme alpha-glucosidase in the small intestine Result: delayed absorption of glucose Must be taken with meals to prevent excessive postprandial blood glucose elevations (with the “first bite” of a meal)
32
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Indications Used alone or in combination with other drugs and/or diet and lifestyle changes to lower the blood glucose levels in patients with type 2 diabetes
33
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Adverse Effects Sulfonylureas Hypoglycemia, hematologic effects, nausea, epigastric fullness, heartburn, many others Meglitinides Headache, hypoglycemic effects, dizziness, weight gain, joint pain, upper respiratory infection or flu-like symptoms
34
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Adverse Effects (cont’d) metformin Primarily affects GI tract: abdominal bloating, nausea, cramping, diarrhea, feeling of fullness May also cause metallic taste, reduced vitamin B 12 levels Lactic acidosis is rare but lethal if it occurs Does not cause hypoglycemia
35
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Adverse Effects (cont’d) Thiazolidinediones Moderate weight gain, edema, mild anemia Hepatic toxicity—monitor ALT levels α-glucosidase inhibitors Flatulence, diarrhea, abdominal pain Do not cause hypoglycemia, hyperinsulinemia, or weight gain
36
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Oral Antidiabetic Drugs: Interactions-Sulfonylureas Sulfonylureas Hypoglycemic effect increases when taken with alcohol, anabolic steroids, many other drugs Adrenergics, corticosteroids, thiazides, others may reduce hypoglycemic effects Allergic cross-sensitivity may occur with loop diuretics and sulfonamide antibiotics May interact with alcohol, causing a disulfiram- type reaction
37
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Other Antidiabetic Drugs Amylin Mimetic: pramlintide (Symlin) Mimics the natural hormone amylin Slows gastric emptying Suppressed glucagon secretion, reducing hepatic glucose output Centrally modulates appetite and satiety Used when other drugs have not achieved adequate glucose control
38
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Other Antidiabetic Drugs (cont’d) Incretin Mimetic: exenatide (Byetta) Mimics the incretin hormones Enhances glucose-driven insulin secretion from β cells of the pancrease Only used for Type 2 diabetes Injection pen device Inhaled Insulin: Exubera
39
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Hypoglycemia Abnormally low blood glucose level (below 50 mg/dL) Mild cases can be treated with diet—higher intake of protein and lower intake of carbs— to prevent a rebound postprandial hypoglycemia
40
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Hypoglycemia Symptoms Early Confusion, irritability, tremor, sweating Later Hypothermia, seizures Coma and death will occur if not treated
41
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Glucose-Elevating Drugs Oral forms of concentrated glucose Buccal tablets, semisolid gel 50% dextrose in water (D 50 W) glucagon diazoxide
42
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antidiabetic Drugs: Nursing Implications Before giving any drugs that alter glucose levels, obtain and document: A thorough history Vital signs Blood glucose level, HbA1c level Potential complications and drug interactions
43
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications Before giving any drugs that alter glucose levels: Assess the patient’s ability to consume food Assess for nausea or vomiting Hypoglycemia may be a problem if antidiabetic drugs are given and the patient does not eat If a patient is NPO for a test or procedure, consult physician to clarify orders for antidiabetic drug therapy
44
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Keep in mind that overall concerns for any diabetic patient increase when the patient: Is under stress Has an infection Has an illness or trauma Is pregnant or lactating
45
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Thorough patient education is essential regarding: Disease process Diet and exercise recommendations Self-administration of insulin or oral drugs Potential complications
46
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) When insulin is ordered, ensure: Correct route Correct type of insulin Timing of the dose Correct dosage Insulin order and prepared dosages are second-checked with another nurse
47
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Insulin Check blood glucose level before giving insulin Roll vials between hands instead of shaking them to mix suspensions Ensure correct storage of insulin vials ONLY insulin syringes, calibrated in units, are to be used to measure and give insulin Ensure correct timing of insulin dose with meals
48
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Insulin (cont’d) When drawing up two types of insulin in one syringe, always withdraw the regular or rapid- acting insulin first Provide thorough patient education regarding self- administration of insulin injections, including timing of doses, monitoring blood glucoses, and injection site rotations
49
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Oral antidiabetic drugs Always check blood glucose levels before giving Usually given 30 minutes before meals Alpha-glucosidase inhibitors are given with the first bite of each main meal Metformin is taken with meals to reduce GI effects
50
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Assess for signs of hypoglycemia If hypoglycemia occurs: Give glucagon or Have the patient eat glucose tablets or gel, corn syrup, honey, fruit juice, or nondiet soft drink or Have the patient eat a small snack such as crackers or half a sandwich Monitor blood glucose levels
51
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Monitor for therapeutic response Decrease in blood glucose levels to the level prescribed by physician Measure hemoglobin A1c to monitor long-term compliance to diet and drug therapy Watch for hypoglycemia and hyperglycemia
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.